Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of ANJ900 in Healthy Chinese Subjects
NCT05151146Phase 1Completed
- Sponsor
- Anji Pharma
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ANJ900 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Anji Pharma. Primary endpoints: Area Under the Curve at 1 week and Maximum Plasma Concentration at 1 week. Started Oct 2021; status: completed.
02
Drugs
ANJ900
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05151146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151146.